SENSUS HEALTHCARE INC (SRTS) Stock Fundamental Analysis
NASDAQ:SRTS - Nasdaq - US81728J1097 - Common Stock
Taking everything into account, SRTS scores 6 out of 10 in our fundamental rating. SRTS was compared to 191 industry peers in the Health Care Equipment & Supplies industry. SRTS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SRTS may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make SRTS a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year SRTS was profitable.
In the past year SRTS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: SRTS reported negative net income in multiple years.
SRTS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SRTS's Return On Assets of 15.56% is amongst the best of the industry. SRTS outperforms 96.32% of its industry peers.
SRTS's Return On Equity of 17.20% is amongst the best of the industry. SRTS outperforms 93.16% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.59%, SRTS belongs to the top of the industry, outperforming 97.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.56% | ||
| ROE | 17.2% | ||
| ROIC | 17.59% |
ROA(3y)18.8%
ROA(5y)5.48%
ROE(3y)22.42%
ROE(5y)5.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRTS has a Profit Margin of 22.54%. This is amongst the best in the industry. SRTS outperforms 94.74% of its industry peers.
The Operating Margin of SRTS (28.91%) is better than 96.32% of its industry peers.
Looking at the Gross Margin, with a value of 60.90%, SRTS is in the better half of the industry, outperforming 62.63% of the companies in the same industry.
SRTS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.91% | ||
| PM (TTM) | 22.54% | ||
| GM | 60.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.68%
GM growth 5Y-2.08%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SRTS is creating value.
The number of shares outstanding for SRTS remains at a similar level compared to 1 year ago.
Compared to 5 years ago, SRTS has more shares outstanding
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SRTS has an Altman-Z score of 14.37. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
SRTS has a better Altman-Z score (14.37) than 91.05% of its industry peers.
There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 14.37 |
ROIC/WACC1.9
WACC9.25%
2.3 Liquidity
SRTS has a Current Ratio of 10.52. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
SRTS's Current ratio of 10.52 is amongst the best of the industry. SRTS outperforms 93.16% of its industry peers.
SRTS has a Quick Ratio of 7.89. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.89, SRTS belongs to the top of the industry, outperforming 92.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.52 | ||
| Quick Ratio | 7.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1050.00% over the past year.
Looking at the last year, SRTS shows a very strong growth in Revenue. The Revenue has grown by 65.63%.
Measured over the past years, SRTS shows a decrease in Revenue. The Revenue has been decreasing by -1.58% on average per year.
EPS 1Y (TTM)1050%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.78%
Revenue 1Y (TTM)65.63%
Revenue growth 3Y36.58%
Revenue growth 5Y-1.58%
Sales Q2Q%126.76%
3.2 Future
Based on estimates for the next years, SRTS will show a very strong growth in Earnings Per Share. The EPS will grow by 148.41% on average per year.
The Revenue is expected to grow by 33.96% on average over the next years. This is a very strong growth
EPS Next Y1362%
EPS Next 2Y366.48%
EPS Next 3Y214.32%
EPS Next 5Y148.41%
Revenue Next Year72.41%
Revenue Next 2Y46.72%
Revenue Next 3Y42.26%
Revenue Next 5Y33.96%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SRTS is valuated correctly with a Price/Earnings ratio of 12.00.
Based on the Price/Earnings ratio, SRTS is valued cheaply inside the industry as 95.79% of the companies are valued more expensively.
SRTS is valuated cheaply when we compare the Price/Earnings ratio to 28.29, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 10.48 indicates a reasonable valuation of SRTS.
Based on the Price/Forward Earnings ratio, SRTS is valued cheaper than 96.32% of the companies in the same industry.
SRTS is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.44, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12 | ||
| Fwd PE | 10.48 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SRTS is valued cheaper than 97.89% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SRTS is valued a bit cheaper than the industry average as 74.74% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.67 | ||
| EV/EBITDA | 7.37 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SRTS's earnings are expected to grow with 214.32% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y366.48%
EPS Next 3Y214.32%
5. Dividend
5.1 Amount
No dividends for SRTS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENSUS HEALTHCARE INC
NASDAQ:SRTS (1/21/2025, 8:00:00 PM)
Premarket: 6.96 +0.12 (+1.75%)6.84
+0.28 (+4.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners20.68%
Inst Owner Change0.52%
Ins Owners17.77%
Ins Owner Change2.02%
Market Cap112.11M
Analysts82
Price Target11.73 (71.49%)
Short Float %9.22%
Short Ratio5.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)553.25%
Min EPS beat(2)320.23%
Max EPS beat(2)786.28%
EPS beat(4)4
Avg EPS beat(4)391.25%
Min EPS beat(4)108.94%
Max EPS beat(4)786.28%
EPS beat(8)5
Avg EPS beat(8)128.69%
EPS beat(12)7
Avg EPS beat(12)93.24%
EPS beat(16)11
Avg EPS beat(16)93.11%
Revenue beat(2)2
Avg Revenue beat(2)38.18%
Min Revenue beat(2)29.36%
Max Revenue beat(2)47%
Revenue beat(4)4
Avg Revenue beat(4)60.38%
Min Revenue beat(4)11.39%
Max Revenue beat(4)153.76%
Revenue beat(8)4
Avg Revenue beat(8)17%
Revenue beat(12)7
Avg Revenue beat(12)18.19%
Revenue beat(16)9
Avg Revenue beat(16)19.92%
PT rev (1m)0%
PT rev (3m)7.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.58%
EPS NY rev (1m)0%
EPS NY rev (3m)16.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12 | ||
| Fwd PE | 10.48 | ||
| P/S | 2.71 | ||
| P/FCF | 53.67 | ||
| P/OCF | 42.13 | ||
| P/B | 2.07 | ||
| P/tB | 2.07 | ||
| EV/EBITDA | 7.37 |
EPS(TTM)0.57
EY8.33%
EPS(NY)0.65
Fwd EY9.54%
FCF(TTM)0.13
FCFY1.86%
OCF(TTM)0.16
OCFY2.37%
SpS2.52
BVpS3.3
TBVpS3.3
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.56% | ||
| ROE | 17.2% | ||
| ROCE | 21.85% | ||
| ROIC | 17.59% | ||
| ROICexc | 29.95% | ||
| ROICexgc | 29.95% | ||
| OM | 28.91% | ||
| PM (TTM) | 22.54% | ||
| GM | 60.9% | ||
| FCFM | 5.06% |
ROA(3y)18.8%
ROA(5y)5.48%
ROE(3y)22.42%
ROE(5y)5.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.68%
GM growth 5Y-2.08%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 273.68% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 21.9% | ||
| Profit Quality | 22.44% | ||
| Current Ratio | 10.52 | ||
| Quick Ratio | 7.89 | ||
| Altman-Z | 14.37 |
F-Score7
WACC9.25%
ROIC/WACC1.9
Cap/Depr(3y)51.53%
Cap/Depr(5y)55.46%
Cap/Sales(3y)0.59%
Cap/Sales(5y)1.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1050%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.78%
EPS Next Y1362%
EPS Next 2Y366.48%
EPS Next 3Y214.32%
EPS Next 5Y148.41%
Revenue 1Y (TTM)65.63%
Revenue growth 3Y36.58%
Revenue growth 5Y-1.58%
Sales Q2Q%126.76%
Revenue Next Year72.41%
Revenue Next 2Y46.72%
Revenue Next 3Y42.26%
Revenue Next 5Y33.96%
EBIT growth 1Y763.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year331.06%
EBIT Next 3Y113.06%
EBIT Next 5Y101.39%
FCF growth 1Y-68.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.55%
OCF growth 3YN/A
OCF growth 5YN/A